BGLC

BioNexus Gene Lab Corp BGLC

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $13.4M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$76.2K

Quarter to Jun 30

Net income

$-286.5K

Quarter to Jun 30

Free cash flow

$-422.7K

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$226 total
UBS Group AG
$197-56.3%
HRT FINANCIAL LP
$27New
Caitong International Asset Management Co., Ltd
$2New
See all 3 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BGLC

Earnings Per Share

13fpro.ai/company/BGLC

Loading ratio trend…

BGLC key financials by period

Reported revenue, net income and operating margin by fiscal year, from BioNexus Gene Lab Corp's annual filings on SEC EDGAR.

BioNexus Gene Lab Corp reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$7.4M$-3.0M-39.9%
FY 2024$9.5M$-1.6M-16.6%
FY 2023$9.8M$-2.6M-26.5%
FY 2022$10.9M$-356.0K-2.7%
FY 2021$13.4M$751.6K7.9%
FY 2020$11.4M$1.1M11.2%
Source: BGLC filings on SEC EDGAR →

BGLC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About BioNexus Gene Lab Corp (BGLC): stock profile, AI score and financials

BioNexus Gene Lab Corp (BGLC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BGLC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $13.4m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), BioNexus Gene Lab Corp reports quarterly revenue of $76.2K, net income of $-286.5K, free cash flow of $-422.7K. Top institutional holders of BGLC by reported 13-F value include UBS Group AG, HRT FINANCIAL, Caitong International Asset Management , Ltd, based on the most recent SEC filings. BGLC trades on the Nasdaq exchange and files with the SEC under CIK 1737523. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BGLC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioNexus Gene Lab Corp directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1737523 →